BioXcel Therapeutics is trading 21.01% down at $0.94 after investors reacted to its second-quarter earnings and revenue miss.
- EPS came in at -$0.490 versus a -$0.423 estimate, while revenue was $182K versus $403.32K expected.
- BioXcel reported $13.8 million in cash, $17.9 million in first-half operating cash burn, and continued losses, with funding reportedly insufficient beyond August 2026.
- The selloff reverses gains from three consecutive advancing sessions.